R-四氢萘甲酸 | 23357-47-3

• 物质功能分类: 化学试剂 - 有机试剂 - 多环化合物
• 分子结构分类: 有机化合物 - 苯类化合物 - 萘
• 中文名称: R-四氢萘甲酸
• 中文别名: (R)-1,2,3,4-四氢-1-萘酸；(R)-(+)-四氢萘甲酸；(R)-1,2,3,4-四氢萘甲酸；(R)-1,2,3,4-四氢-1-萘甲酸
• 英文名称: (R)-1,2,3,4-tetrahydronaphthalene-1-carboxylic acid
• 英文别名: (R)-1,2,3,4-tetrahydro-1-naphthoic acid；R-1,2,3,4-tetrahydro-1-naphthoic acid；(R)-1,2,3,4-tetrahydronaphthoic acid；(R)-1.2.3.4-tetrahydro-naphthoic acid-(1)；(R)-1.2.3.4-Tetrahydro-naphthoesaeure-(1)；(R)-1,2,3,4-Tetrahydro-[1]naphthoesaeure；(1R)-1,2,3,4-Tetrahydronaphthalene-1-carboxylic acid
• CAS: 23357-47-3
• 化学式: C₁₁H₁₂O₂
• mdl: MFCD02179127
• 分子量: 176.215
• InChiKey: VDLWTJCSPSUGOA-SNVBAGLBSA-N

物化性质

• 熔点：
  56-58℃
• 沸点：
  54-56°C
• 密度：
  1.186±0.06 g/cm3(Predicted)
• 溶解度：
  可溶于乙酸乙酯（少许）、甲醇（少许）
• 稳定性/保质期：

  如果按照规定使用和储存，则不会分解。请避免接触氧化物。

计算性质

• 辛醇/水分配系数(LogP)：
  2.4
• 重原子数：
  13
• 可旋转键数：
  1
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.36
• 拓扑面积：
  37.3
• 氢给体数：
  1
• 氢受体数：
  2

安全信息

• 危险品标志：
  Xn
• 安全说明：
  S26
• 危险类别码：
  R22,R36,R51
• 海关编码：
  2916399090
• 危险性防范说明：
  P261,P305+P351+P338
• 危险性描述：
  H315,H319,H335

SDS

Material Safety Data Sheet

---

Section 1. Identification of the substance
Product Name: (R)-1,2,3,4-Tetrahedronaphthoic acid
Synonyms:

---

Section 2. Hazards identification
Harmful by inhalation, in contact with skin, and if swallowed.
H302: Harmful if swallowed
H319: Causes serious eye irritation
H411: Toxic to aquatic life with long lasting effects
P273: Avoid release to the environment
P305+P351+P338: IF IN EYES: Rinse cautiously with water for several minutes. Remove contact lenses if present
and easy to do – continue rinsing

---

Section 3. Composition/information on ingredients.
Ingredient name: (R)-1,2,3,4-Tetrahedronaphthoic acid
CAS number: 23357-47-3

---

Section 4. First aid measures
Skin contact: Immediately wash skin with copious amounts of water for at least 15 minutes while removing
contaminated clothing and shoes. If irritation persists, seek medical attention.
Immediately wash skin with copious amounts of water for at least 15 minutes. Assure adequate
Eye contact:
flushing of the eyes by separating the eyelids with fingers. If irritation persists, seek medical
attention.
Inhalation: Remove to fresh air. In severe cases or if symptoms persist, seek medical attention.
Ingestion: Wash out mouth with copious amounts of water for at least 15 minutes. Seek medical attention.

---

Section 5. Fire fighting measures
In the event of a fire involving this material, alone or in combination with other materials, use dry
powder or carbon dioxide extinguishers. Protective clothing and self-contained breathing apparatus
should be worn.

---

Section 6. Accidental release measures
Personal precautions: Wear suitable personal protective equipment which performs satisfactorily and meets local/state/national
standards.
Respiratory precaution: Wear approved mask/respirator
Hand precaution: Wear suitable gloves/gauntlets
Skin protection: Wear suitable protective clothing
Eye protection: Wear suitable eye protection
Methods for cleaning up: Mix with sand or similar inert absorbent material, sweep up and keep in a tightly closed container
for disposal. See section 12.
Environmental precautions: Do not allow material to enter drains or water courses.

---

Section 7. Handling and storage
Handling: This product should be handled only by, or under the close supervision of, those properly qualified
in the handling and use of potentially hazardous chemicals, who should take into account the fire,
health and chemical hazard data given on this sheet.
Storage: Store in closed vessels.

---

Section 8. Exposure Controls / Personal protection
Engineering Controls: Use only in a chemical fume hood.
Personal protective equipment: Wear laboratory clothing, chemical-resistant gloves and safety goggles.
General hydiene measures: Wash thoroughly after handling. Wash contaminated clothing before reuse.

---

Section 9. Physical and chemical properties
Appearance: Not specified
No data
Boiling point:
Melting point: No data
Flash point: No data
Density: No data
Molecular formula: C11H12O2
Molecular weight: 176.2

---

Section 10. Stability and reactivity
Conditions to avoid: Heat, flames and sparks.
Materials to avoid: Oxidizing agents.
Possible hazardous combustion products: Carbon monoxide.

---

Section 11. Toxicological information
No data.

---

Section 12. Ecological information
No data.

---

Section 13. Disposal consideration
Arrange disposal as special waste, by licensed disposal company, in consultation with local waste
disposal authority, in accordance with national and regional regulations.

---

Section 14. Transportation information
Non-harzardous for air and ground transportation.

---

Section 15. Regulatory information
No chemicals in this material are subject to the reporting requirements of SARA Title III, Section
302, or have known CAS numbers that exceed the threshold reporting levels established by SARA
Title III, Section 313.

---

SECTION 16 - ADDITIONAL INFORMATION
N/A

反应信息

• 作为反应物：
  描述：

  R-四氢萘甲酸 在 lithium aluminium tetrahydride 作用下， 以 乙醚 为溶剂， 反应 2.0h， 以97%的产率得到(R)-(1,2,3,4-tetrahydronaphthalen-1-yl)methanol
  参考文献：
  名称：

  对人蛋白酶体β2c或β2i亚基有选择性的抑制剂的基于结构的设计。

  摘要：

  亚单位选择性蛋白酶体抑制剂是评估单个蛋白酶体活性位点生物学和医学相关性的有价值的工具。尽管β1c，β1i，β5c和β5i亚基的抑制剂利用了X射线晶体学鉴定的底物结合通道的差异，但由于这些化合物的高度结构相似性，因此尚无法合理设计选择性靶向β2c或β2i的​​化合物两个亚单位。在这里，我们报告了一个化合物库的开发，化学合成和生物学筛选，该过程导致了对β2c和β2i选择性化合物LU-002c的鉴定（4； IC50β2c：8 nM，IC50β2i/β2c：40-倍数）和LU-002i（5; IC50β2i：220 nM，IC50β2c/β2i：45倍）。具有β2人源化酵母蛋白酶体的共晶体结构可可视化对于亚基特异性至关重要的蛋白质-配体相互作用。总而言之，有机合成，基于活性的蛋白质谱分析，酵母诱变和结构生物学使我们能够破译β2底物结合通道的显着差异，并完成了一组亚基选择性蛋白酶体抑制剂的研究。

  DOI：

  10.1021/acs.jmedchem.8b01884
• 作为产物：
  描述：

  1,2,3,4-四氢-1-萘甲酸 生成 R-四氢萘甲酸
  参考文献：
  名称：

  Westman, Arkiv foer Kemi, 1958, vol. 12, p. 161,165

  摘要：

  DOI：

文献信息

• [EN] SPIROCYCLIC COMPOUNDS<br/>[FR] COMPOSÉS SPIROCYCLIQUES
  申请人：C4 THERAPEUTICS INC

  公开号：WO2019204354A1

  公开（公告）日：2019-10-24

  The present invention provides compounds which bind to the ubiquitously expressed E3 ligase protein cereblon (CRBN) and their use for the treatment of abnormal cellular proliferation. The present invention also provides compounds that may be used as synthetic intermediates in the synthesis of bifunctional compounds used for targeted protein degradation.

  本发明提供了结合到普遍表达的E3连接酶蛋白Cereblon（CRBN）的化合物，以及它们用于治疗异常细胞增殖的用途。本发明还提供了可用作合成双功能化合物的中间体的化合物，用于靶向蛋白降解的合成。
• MICROBIOCIDAL HETEROCYCLES
  申请人：Sulzer-Mosse Sarah

  公开号：US20120142700A1

  公开（公告）日：2012-06-07

  The present invention relates to heterocyclic compounds of formula (I) which have microbiocidal activity, in particular fungicidal activity, as well as methods of using the compounds of formula (I) to control microbes.

  本发明涉及具有微生物杀灭活性的杂环化合物(I)的公式，特别是具有真菌杀灭活性，以及使用公式(I)化合物控制微生物的方法。
• 一种高效拆分制备(S)-四氢-1-萘甲酸的方法
  申请人：杭州新博思生物医药有限公司

  公开号：CN107382697A

  公开（公告）日：2017-11-24

  本发明涉及一种式（I）所示的盐酸帕洛诺司琼关键中间体(S)‑1,2,3,4‑四氢‑1‑萘甲酸的制备方法，该方法包括以下步骤：以1,2,3,4‑四氢萘甲酸消旋体为原料加入拆分剂拆分，得到（S）‑1,2,3,4‑四氢萘甲酸与拆分剂形成的盐（III）和（R）‑1,2,3,4‑四氢萘甲酸与拆分剂形成的盐（IV）；再对化合物III和化合物IV分别进行解盐，得到化合物（I）和（II）；将化合物（II）在碱性条件下进行消旋，得到起始原料1,2,3,4‑四氢萘甲酸消旋体，继续按上述步骤拆分。如此循环，可以大大提高总体收率，降低生产成本，更有利于环境保护。本发明提供了一种与现有技术不同的，安全环保、操作简单、收率高、具有较大实用价值的盐酸帕洛诺司琼关键中间体的制备工艺。
• Amide Derivatives as Kinase Inhibitors
  申请人：Defert Olivier Raynald

  公开号：US20090118283A1

  公开（公告）日：2009-05-07

  The present invention relates to new AGC kinase inhibitors, in particular to compounds of Formula (I) or (II) or a stereoisomer tautomer, racemic, metabolite, pro- or predrug, salt, hydrate, or solvate thereof, wherein Ar 1 , Ar 2 , R 1 , R 3 , p and n have the meaning defined in the claims In particular, the present invention relates to more specifically AGC kinases inhibitors, compositions, in particular pharmaceuticals, comprising such inhibitors, and to uses of such inhibitors in the treatment and prophylaxis of disease.

  本发明涉及新的AGC激酶抑制剂，特别是公式（I）或（II）的化合物或其立体异构体、互变异构体、外消旋体、代谢物、前药或前药、盐、水合物或溶剂化物，其中Ar1、Ar2、R1、R3、p和n在权利要求中定义。特别地，本发明涉及更具体的AGC激酶抑制剂、包含这种抑制剂的组合物，特别是药物，以及在治疗和预防疾病中使用这种抑制剂的用途。
• SUBSTITUTED BENZOYLAMINO-INDAN-2-CARBOXYLIC ACIDS AND RELATED COMPOUNDS
  申请人：CAULFIELD Thomas J.

  公开号：US20100113462A1

  公开（公告）日：2010-05-06

  The present invention relates to novel compounds of the formula I: wherein in any of its stereoisomeric forms or a mixture of stereoisomeric forms in any ratio, or a physiologically acceptable salt thereof, wherein the substituents are as described herein. The inventive compounds have CXCR5 inhibitory activity are particularly useful in treating or preventing various inflammatory diseases, such as rheumatoid arthritis, multiple sclerosis, lupus, Crohn's Disease, associated with the modulation of the human CXCR5 receptor.

  本发明涉及公式I的新化合物：其中在其任何立体异构形式或立体异构形式的混合物中以任何比例，或其生理上可接受的盐，其中取代基如此描述。这些创新化合物具有CXCR5抑制活性，特别适用于治疗或预防各种炎症性疾病，例如类风湿性关节炎，多发性硬化症，红斑狼疮，克罗恩病，与人类CXCR5受体调节相关。